CTOs on the Move

Minute Molecular Diagnostics

www.m2dx.com

 
Minute Molecular Diagnostics was founded in 2017 as a spinout of the Northwestern University Center for Innovation in Global Health Technology (CIGHT). Comprised of a strong management team with extensive diagnostic industry experience, the company has raised $8 million in funding from the NIH and Diagnostic Industry Executives.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.m2dx.com
  • 1800 Sherman Avenue Suite 504
    Evanston, IL USA
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Minute Molecular Diagnostics raised $21.3M on 04/22/2021

Similar Companies

Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA™) platform, in combination with Cabaletta`s proprietary technology, utilizes CAAR T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company`s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please visit our website ( DesCAARTes™ Phase 1 Trial ). The Company`s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.

Cortexyme

Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer`s and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.

High Point Clinical Trials Center

High Point Clinical Trials Center is committed to the safe and ethical conduct of clinical trials for investigational drugs in a pleasant, comfortable environment for research participants. We recognize the importance of your decision to participate in a clinical trial and strive to guide you through the process with a knowledgeable and exciting experience. Your decision of being a research participant today may benefit generations to come. Our research trials and clinical studies include research on Alzheimer`s, diabetes, overweight and healthy individuals, and encompass individuals from the Greensboro, Winston-Salem, High Point areas of North Carolina, as well as throughout the US. We offer spacious comfortable living quarters, entertainment areas (media and games rooms), catered meals and wireless internet service for our participants. High Point Clinical Trials Center offers clinical studies and trials for Greensboro, Winston Salem, High Point residents, as well as throughout the US.

Good Therapeutics

Good Therapeutics is an early-stage biotechnology company based in Seattle, Washington. We are developing "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. Our goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy.

SeniorBridge Family

SeniorBridge Family is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.